Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.44 |
| ▸ | CES2 | O00748 | 1/20 | 0.44 |
| ▸ | GALR3 | O60755 | 1/20 | 0.44 |
| ▸ | GLA | P06280 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CASP1 | P29466 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | LCK | P06239 | 1/20 | 0.41 |
| ▸ | DHODH | Q02127 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23640511 | 0.84 | ERN1 (0.54) | ERN1MEN1KMT2AMAPTALDH1A1 | |
| SCHEMBL15528059 | 0.82 | RXFP1 (0.53) | ERN1MEN1KMT2ARXFP1MAPT | |
| SCHEMBL732139 | 0.81 | CA12 (0.48) | ERN1MEN1KMT2AALDH1A1CYP1A2 | |
| SCHEMBL30178354 | 0.81 | CA12 (0.48) | ERN1MEN1KMT2AALDH1A1CYP1A2 | |
| SCHEMBL3978695 | 0.81 | KDM4E (0.53) | ERN1MEN1KMT2ARXFP1MAPT | |
| SCHEMBL4751251 | 0.81 | ALDH1A1 (0.48) | ERN1MEN1KMT2ARXFP1MAPT | |
| SCHEMBL13573125 | 0.81 | CA1 (0.50) | ERN1MEN1KMT2AMAPTALDH1A1 | |
| SCHEMBL4027557 | 0.80 | ERN1 (0.50) | ERN1MEN1KMT2ARXFP1MAPT | |
| SCHEMBL3914003 | 0.80 | KDM4E (0.53) | ERN1MEN1KMT2AMAPTALDH1A1 | |
| SCHEMBL29322563 | 0.80 | ERN1 (0.47) | ERN1MEN1KMT2ARXFP1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1222174-B1 | IMIDAZOL-4-YLMETHANOLS USED AS INHIBITORS OF STEROID C17-20 LYASE | TAKEDA PHARMACEUTICAL (JP) | 2009-05-27 | — | — | EP | disclosed |
| US-7276512-B2 | Benzo[a]pyrano[3,2-h]acridin-7-one compounds | LES LABORATOIRES SERVIER (FR) | 2007-10-02 | — | — | US | disclosed |
| CN-1289502-C | New derivatives of benzo[a]pyrano[3,2-h]acridin-7-one, a process for their preparation and pharmaceutical compounds containing them | SERVIER LAB (FR) | 2006-12-13 | — | — | CN | disclosed |
| CN-1576277-A | New derivatives of benzo[a]pyrano[3,2-h]acridin-7-one, a process for their preparation and pharmaceutical compounds containing them | SERVIER LAB (FR) | 2005-02-09 | — | — | CN | disclosed |
| US-20040266753-A1 | Benzo[a]pyrano[3,2-h]acridin-7-one compounds | LES LABORATOIRES SERVIER (FR) | 2004-12-30 | — | — | US | disclosed |
| US-6649643-B1 | Antitumor, anticarcinogenic, and antimetastasis agents; benign prostatic hyperplasia, alopecia, endometriosis, uterine myoma, hirsutism, virilism, precocious puberty, mastopathy, and polycystic overay syndrome treatment | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2003-11-18 | — | — | US | disclosed |
| EP-1222174-A1 | IMIDAZOL-4-YLMETHANOLS USED AS INHIBITORS OF STEROID C17-20 LYASE | Takeda Chemical Industries, Ltd. (JP) | 2002-07-17 | — | — | EP | disclosed |
| WO-2001030762-A1 | IMIDAZOL-4-YLMETHANOLS USE AS INHIBITORS OF STEROID C17-20 LYASE | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-05-03 | — | — | WO | disclosed |
| US-4137272-A | Process for the manufacture of 2-alkoxy-6-bromo-naphthalenes | HOECHST AKTIENGESELLSCHAFT (DE) | 1979-01-30 | — | — | US | disclosed |
| US-4137272-A | Process for the manufacture of 2-alkoxy-6-bromo-naphthalenes | HOECHST AKTIENGESELLSCHAFT (DE) | 1979-01-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040266753-A1 | Benzo[a]pyrano[3,2-h]acridin-7-one compounds | CBR1, AHR, AR | ERN1 2245/4885MEN1 4527/4885KMT2A 1458/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.